Cite
Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study.
MLA
Abplanalp, Wesley Tyler, et al. “Efficiency and Target Derepression of Anti-MiR-92a: Results of a First in Human Study.” Nucleic Acid Therapeutics, vol. 30, no. 6, Dec. 2020, pp. 335–45. EBSCOhost, https://doi.org/10.1089/nat.2020.0871.
APA
Abplanalp, W. T., Fischer, A., John, D., Zeiher, A. M., Gosgnach, W., Darville, H., Montgomery, R., Pestano, L., Allée, G., Paty, I., Fougerousse, F., & Dimmeler, S. (2020). Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. Nucleic Acid Therapeutics, 30(6), 335–345. https://doi.org/10.1089/nat.2020.0871
Chicago
Abplanalp, Wesley Tyler, Ariane Fischer, David John, Andreas M. Zeiher, Willy Gosgnach, Helene Darville, Rusty Montgomery, et al. 2020. “Efficiency and Target Derepression of Anti-MiR-92a: Results of a First in Human Study.” Nucleic Acid Therapeutics 30 (6): 335–45. doi:10.1089/nat.2020.0871.